Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Inclusion Criteria: * The subject has histologically confirmed diagnosis at any time of grade IV astrocytic tumor as determined by the investigator. Tumor samples will be required for pathology review. * The subject has received prior standard radiation for any grade astrocytic tumor. * The subject has received prior temozolomide (Temodar) therapy * The subject has had one or two progressions as grade IV astrocytic tumor from any grade, as determined by investigator * The subject must have a qualifying brain MRI scan within a specific timeframe prior to start of study treatment * For subjects with recent tumor resection or biopsy, starting on study must occur a specified amount of time after the surgery and the subject must have recovered from the effects of surgery * The subject has a Karnofsky Performance Status ≥ 70% and has the ability to swallow whole capsules * The subject is capable of understanding the informed consent and has signed the informed consent document * The subject has adequate organ and marrow function * Sexually active subjects (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 6 months following discontinuation of study treatment * The subject has had no other diagnosis of malignancy (certain exceptions apply) * Female subjects of childbearing potential must have a negative pregnancy test at screening Exclusion Criteria: * The subject has received certain prior anticancer therapies within a certain amount of time before starting study treatment * The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin * The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible * The subject is unable to undergo MRI scan (eg, has pacemaker) * The subject has received enzyme-inducing anti-epileptic agents within a certain time prior to starting study treatment (eg, carbamazepine, phenytoin, phenobarbital, primidone) * The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤ 1 from AEs (except alopecia and lymphopenia) due to surgery, or other medications that were administered prior to study start * The subject has evidence of unhealed wounds * The subject is pregnant or breast-feeding * The subject has serious intercurrent illness or a recent history of serious disease * The subject has inherited bleeding diathesis or coagulopathy (disease affecting how blood clots) with the risk of bleeding * The subject has a history of any medical or surgical conditions (eg, stomach or intestinal surgery or resection) that would potentially interfere with or alter gastrointestinal function * The subject has a history of idiopathic pulmonary fibrosis or interstitial lung disease * The subject has received any live virus vaccine or any inactivated vaccine within a certain amount of time before starting study treatment